Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

BMRA Overall Winner 6-Pillar Tally: BMRA 4 – 1 PACB (1 Tie) Matrix Metrics: BMRA 4 – 4 PACB

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.89 (N/M Forward P/E, -333.0% operating margin).

  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs PACB
BMRA NASDAQ Head-to-Head Winner
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 112% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 15.0 Fund 36.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.4 · SMA20: $2.29 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (BMRA 4 – 1 PACB)

Columns: Metric · BMRA · PACB
1. Valuation Multiples BMRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.1x 7.8x
2. Growth & Scale PACB
Revenue Growth (YoY) -8.3% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.3M $161M
Market Cap $6.0M $615.1M
3. Profitability & Quality BMRA
Gross Margin 0.9% 27.7%
Operating Margin -125.2% -333.0%
Net Profit Margin -115.5% -81.3%
Return on Equity (ROE) -113.8% -929.3%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$3.2M -$150M
Cash Flow Margin -73.5% -93.2%
Net Cash / Leverage $1.1M Net Cash $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 92.6% (47th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (4) vs PACB (4)
Institutional Metric BMRA PACB Criterion Row Edge
Market Capitalization
Scale
$6.0M $615.1M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-8.3% +5.5% Higher Growth PACB
Operating Margin (TTM)
Profitability
-125.2% -333.0% Higher Margin BMRA
Net Profit Margin
Profitability
-115.5% -81.3% Higher Margin PACB
Return on Equity (ROE)
Capital Efficiency
-113.8% -929.3% Higher ROE BMRA
52-Week Range Position
Momentum
5% ($1–$3) 34% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 2.27β · 112% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +35.45 pp
BMRA: -26.49% · PACB: +8.96%
3M Horizon PACB +80.35 pp
BMRA: -15.0% · PACB: +65.35%
6M Horizon PACB +103.47 pp
BMRA: -39.56% · PACB: +63.91%
1Y Horizon PACB +61.24 pp
BMRA: -45.6% · PACB: +15.64%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue PACB Revenue BMRA Op. Margin PACB Op. Margin Margin Leader
FY2019 $10M $90M -46.4% -110.6% BMRA
FY2020 $10M $80M -41.0% -132.3% BMRA
FY2021 $10M $130M -104.2% -161.2% BMRA
FY2022 $20M $130M -24.0% -239.4% BMRA
FY2023 $10M $200M -135.3% -166.8% BMRA
FY2024 $10M $150M -117.6% -308.0% BMRA
FY2025 $10M $160M -96.7% -346.2% BMRA
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs PACB Key Questions & Quantitative Answers

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.89 (N/M Forward P/E, -333.0% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while PACB shifted +77.8%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

BMRA screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.